|
Models used for analysis of the effects of statins on incidence of dementia using the Cox proportional survival method. |
||||||||||||
| Model 1 |
Model 2 |
Model 3 |
||||||||||
|
|
||||||||||||
| Variable |
HR |
p value |
95% Confidence limits for HR |
HR |
p value |
95% Confidence limits for HR |
HR |
p value |
95% Confidence limits for HR |
|||
|
|
||||||||||||
| Atorvastatin |
||||||||||||
| Versus CV |
0.80 |
0.0005 |
0.71 |
0.91 |
0.90 |
0.09 |
0.79 |
1.02 |
0.91 |
0.11 |
0.80 |
1.02 |
| Age |
1.11 |
<0.0001 |
1.10 |
1.12 |
1.11 |
<0.0001 |
1.10 |
1.11 |
||||
| Hypertension |
1.10 |
0.0590 |
1.00 |
1.20 |
||||||||
| CVD |
1.13 |
0.0005 |
1.05 |
1.20 |
||||||||
| Diabetes |
1.12 |
0.0009 |
1.05 |
1.20 |
||||||||
| Charlson Index |
1.78 |
<0.0001 |
1.66 |
1.91 |
||||||||
| Lovastatin |
||||||||||||
| Versus CV |
0.98 |
0.70 |
0.89 |
1.08 |
0.95 |
0.32 |
0.86 |
1.05 |
0.95 |
0.34 |
0.86 |
1.05 |
| Age |
1.11 |
<0.0001 |
1.10 |
1.12 |
1.11 |
<0.0001 |
1.10 |
1.11 |
||||
| Hypertension |
1.09 |
0.07 |
0.99 |
1.19 |
||||||||
| CVD |
1.12 |
0.0005 |
1.05 |
1.20 |
||||||||
| Diabetes |
1.12 |
0.0009 |
1.05 |
1.20 |
||||||||
| Charlson Index |
1.74 |
<0.0001 |
1.62 |
1.86 |
||||||||
| Simvastatin |
||||||||||||
| Versus CV |
0.45 |
<0.0001 |
0.43 |
0.47 |
0.45 |
<0.0001 |
0.43 |
0.48 |
0.46 |
<0.0001 |
0.44 |
0.48 |
| Age |
1.11 |
<0.0001 |
1.10 |
1.11 |
1.11 |
<0.0001 |
1.10 |
1.11 |
||||
| Hypertension |
1.07 |
0.07 |
1.00 |
1.15 |
||||||||
| CVD |
1.09 |
0.0012 |
1.04 |
1.15 |
||||||||
| Diabetes |
1.08 |
0.0034 |
1.03 |
1.14 |
||||||||
| Charlson Index |
1.72 |
<0.0001 |
1.63 |
1.81 |
||||||||
|
HR, hazard ratio, CVD, cardiovacular disease, CV, cardiovascular. Model 1 included an adjustment for the interaction between dementia and age; model 2 included adjustments for the interaction between dementia and three disorders associated with increased risk of dementia.; model 3 included adjustments for the interaction between dementia and the Charlson Index, which is an index that provides a broad assessment for the amount of chronic disease. For the purpose of analysis of interactions with the Charlson Index, subjects with a Charlson Index of 0 or 1 were compared with those with a Charlson Index of ≥2. | ||||||||||||
Wolozin et al. BMC Medicine 2007 5:20 doi:10.1186/1741-7015-5-20 |
||||||||||||